Search results for "Pharmacokinetic"

showing 10 items of 474 documents

Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine

1977

The effect of cholestyramine (12 gm/day divided into 3 doses) on the pharmacokinetics and pharmacodynamics of a single intravenouse dose (30 mg) of phenprocoumon was studied in 6 normal subjects. Cholestyramine treatment led to an increase in the rate of elimination of phenprocoumon in all. Total clearance increased 1.5- to 2-fold. The total anticoagulant effect per dose was considerably reduced during treatment with cholestyramine. Binding studies in vitro showed that phenprocoumon is strongly bound to cholestyramine and that at a given cholestyramine concentration the percentage of phenprocoumon bound remained constant over a large concentration range of phenprocoumon. The results suggest…

AdultMalePharmacologyCholestyramineAnticoagulant effectDose-Response Relationship DrugChemistryCholestyramine Resin4-HydroxycoumarinsMiddle AgedPharmacologyPhenprocoumonLiverPharmacokineticsEnterohepatic CirculationPhenprocoumonmedicineHumansPharmacology (medical)Enterohepatic circulationHalf-Lifemedicine.drugClinical Pharmacology & Therapeutics
researchProduct

Pharmacokinetics, pharmacodynamics, and safety of moss-aGalactosidase A in patients with Fabry disease.

2019

Moss-aGalactosidase A (moss-aGal) is a moss-derived version of human α-galactosidase developed for enzyme replacement therapy in patients with Fabry disease. It exhibits a homogenous N-glycosylation profile with >90% mannose-terminated glycans. In contrast to mammalian cell produced α-galactosidase, moss-aGal does not rely on mannose-6-phosphate receptor mediated endocytosis but targets the mannose receptor for tissue uptake. We conducted a phase 1 clinical trial with moss-aGal in six patients with confirmed diagnosis of Fabry disease during a 28-day schedule. All patients received a single dose of 0.2 mg/kg moss-aGal by i.v.-infusion. Primary endpoints of the trial were safety and pharmaco…

AdultMalePhases of clinical researchPharmacologyExcretion03 medical and health sciencesPharmacokineticsGermanyGeneticsmedicineHumansEnzyme Replacement TherapyInfusions IntravenousGenetics (clinical)030304 developmental biology0303 health sciencesKidneySphingolipidsbusiness.industry030305 genetics & heredityEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseasemedicine.anatomical_structureTreatment OutcomePharmacodynamicsalpha-GalactosidaseFabry DiseaseFemaleGlycolipidsbusinessMannose receptorJournal of inherited metabolic disease
researchProduct

Gender differences in adverse drug reactions in dermatological patients in west Sicily: an epidemiological study

2013

Purpose: The purpose of this study was to show that gender also plays an important role in pharmacokinetics, pharmacodynamics, and drug toxicity. It is only fair to take into account the so-called “gender-based medicine.” Methods: We again selected admission for cutaneous adverse drug reaction (CADRs), from January 2012 to July 2012, in order to detect and verify, in an analytical way, the substantial gender differences in adverse drug reactions in term incidence, clinical manifestations, severity and drugs involved. Results:In the period January–July 2012, at the Department of Dermatology and Sexually Transmitted Disease of A.O.U.P. “Paolo Giaccone” Palermo, 384 patients were admitted, of …

AdultMaleSexually transmitted diseasemedicine.medical_specialtyDermatologyPharmacologySex FactorsPharmacokineticsInternal medicineEpidemiologyPharmacovigilancemedicineSettore MED/35 - Malattie Cutanee E VenereeHumansSicilyRetrospective Studiesbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyadverse drug reactions gender-based medicine pharmacovigilanceMiddle Agedmedicine.diseasePharmacodynamicsFemaleDrug EruptionsbusinessAdverse drug reaction
researchProduct

Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study

2017

Background and aims: Patients on parenteral nutrition for short bowel syndrome (SBS) have a high risk of thrombotic complications and are often treated with parenteral anticoagulation. Direct oral anticoagulants are absorbed proximally in the digestive tract and may represent alternative regimens in selected SBS patients. In our pilot study, we provided pharmacokinetics parameters of dabigatran etexilate and rivaroxaban in this setting and compared peak (Cmax), trough (Ctrough) concentrations, and areas-under-the-concentration-time-curve (AUC(0) (-) (t)) to reference values retrieved from phase I-III studies. Methods: We enrolled 6 adults with a remaining small bowel length <= 200 cm, norma…

AdultMaleShort Bowel SyndromeParenteral Nutritionmedicine.medical_specialtyCmax030204 cardiovascular system & hematologyGastroenterologyAntithrombinsDabigatran03 medical and health sciences0302 clinical medicineRivaroxabanPharmacokineticsInternal medicinemedicineHumans030212 general & internal medicineDosingAgedRivaroxabanbusiness.industryHematologyMiddle AgedShort bowel syndromemedicine.diseaseCrossover studyDabigatranParenteral nutritionAnesthesiaFemalebusinessmedicine.drugThrombosis Research
researchProduct

Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine

2003

INTRODUCTION Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly a…

AdultMaleSleep Wake Disordersmedicine.medical_specialtyMelperoneVenlafaxine HydrochlorideVenlafaxinePharmacologyMethylationPharmacokineticsOral administrationCytochrome P-450 CYP2D6 InhibitorsInternal medicineDextrorphanmedicineHumansDrug InteractionsPharmacology (medical)AgedRetrospective StudiesChemistryVenlafaxine HydrochlorideGeneral MedicineDextromethorphanMiddle AgedCyclohexanolsButyrophenonesPsychiatry and Mental healthEndocrinologyCytochrome P-450 CYP2D6Drug Therapy CombinationFemaleDrug MonitoringReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients

1997

Little information exists on the concentrations of antidepressants and their metabolites in CSF. We measured plasma and CSF levels of trans-doxepin (trans-DOX) and DOX metabolites in 12 depressed patients treated with DOX (250 mg/day) for 6 days. Spinal taps and blood samples were taken on day 7, 10 h after drug administration. Trans-DOX, cis-desmethyldoxepin (cis-DM-DOX), trans-desmethyldoxepin (trans-DM-DOX) and di-desmethyldoxepin (DDM-DOX) were analyzed in CSF and plasma samples by HPLC with column-switching. Although DOX was given as a mixture of 85% trans-DOX and 15% of the pharmacologically more active cis-DOX, we found similar amounts of cis-DM-DOX and trans-DM-DOX in plasma (59.8 +…

AdultMaleSpinal tapMetabolitemedicine.medical_treatmentmacromolecular substancesPharmacologyHigh-performance liquid chromatographychemistry.chemical_compoundCerebrospinal fluidPharmacokineticspolycyclic compoundsmedicineHumansActive metaboliteCerebrospinal FluidPharmacologyDepressive DisorderChemotherapyorganic chemicalstechnology industry and agricultureMiddle AgedDoxepinfilm.actorcarbohydrates (lipids)chemistryfilmFemaleDoxepinmedicine.drugPsychopharmacology
researchProduct

Concentrations of  9-Tetrahydrocannabinol and 11-Nor-9-Carboxytetrahydrocannabinol in Blood and Urine After Passive Exposure to Cannabis Smoke in a C…

2010

Cannabinoid concentrations in blood and urine after passive exposure to cannabis smoke under real-life conditions were investigated in this study. Eight healthy volunteers were exposed to cannabis smoke for 3 h in a well-attended coffee shop in Maastricht, Netherlands. An initial blood and urine sample was taken from each volunteer before exposure. Blood samples were taken 1.5, 3.5, 6, and 14 h after start of initial exposure, and urine samples were taken after 3.5, 6, 14, 36, 60, and 84 h. The samples were subjected to immunoassay screening for cannabinoids and analyzed using gas chromatography-mass spectrometry (GC-MS) for Delta(9)-tetrahydrocannabinol (THC), 11-nor-hydroxy-Delta(9)-tetra…

AdultMaleTime FactorsHealth Toxicology and Mutagenesismedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayUrineToxicologyGas Chromatography-Mass SpectrometryAnalytical ChemistryPharmacokineticsLimit of DetectionSmokemental disordersmedicineHumansEnvironmental ChemistryDronabinolSolid phase extractionVolunteerCannabisNetherlandsInhalation exposureInhalation ExposureChemical Health and SafetyChromatographymedicine.diagnostic_testChemistryorganic chemicalsReproducibility of ResultsMiddle AgedAir Pollution IndoorImmunoassayFemaleCannabinoidGas chromatography–mass spectrometryJournal of Analytical Toxicology
researchProduct

Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery.

2003

The alteration of vancomycin pharmacokinetics during cardiopulmonary bypass (CPB) in patients undergoing cardiac surgery was studied. Eighteen patients were enrolled in the study. Vancomycin (1 g) was intravenously infused one to two hours before surgery. Blood samples were taken before, during, and after CPB. Serum drug concentrations were determined by an automated fluorescence polarization immunoassay and adjusted, with a bayesian analysis, to a bi-compartmental model implemented in a pharmacokinetic system program. Serum creatinine, hematocrit, and plasma proteins were also measured before, during, and after CPB. During CPB, serum creatinine, hematocrit, and plasma protein values all de…

AdultMaleTime FactorsHematocritlaw.inventionchemistry.chemical_compoundPharmacokineticslawVancomycinBlood plasmaCardiopulmonary bypassMedicineHumansInfusions IntravenousAgedMonitoring PhysiologicPharmacologyVolume of distributionCreatinineCardiopulmonary Bypassmedicine.diagnostic_testbusiness.industryHealth PolicyAntibiotic ProphylaxisMiddle AgedBlood proteinsAnti-Bacterial Agentssurgical procedures operativechemistryAnesthesiaVancomycinFemalebusinesscirculatory and respiratory physiologymedicine.drugHalf-LifeAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
researchProduct

Opioid Plasma Concentrations during a Switch from Transdermal Fentanyl to Methadone

2007

Opioid switching is often used to improve the opioid response in patients with cancer experiencing poor analgesia or adverse effects. When switching between drugs with delayed effect because of pharmacokinetics or type of delivery, concerns exist about the correct timing of introducing the second drug after stopping the previous one. The aim of this study was to assess plasmatic changes of fentanyl and methadone underlying the clinical events occurring during opioid switching. Eighteen patients with cancer receiving transdermal fentanyl with uncontrolled pain and/or moderate to severe opioid adverse effects, were switched to oral methadone using an initial fixed ratio of 1:20. Fentanyl patc…

AdultMaleTime FactorsPalliative careAdministration Cutaneousmethadone.Drug Administration ScheduleFentanylPharmacokineticsNeoplasmsHumansMedicineAdverse effectGeneral NursingAgedPain MeasurementTransdermalbusiness.industrywitchingPalliative CareOpioid plasma concentrationGeneral MedicineMiddle Agedtransdermal fentanylPain IntractableAnalgesics OpioidFentanylTreatment OutcomeAnesthesiology and Pain MedicineOpioidBasal (medicine)AnesthesiaFemalebusinessMethadonemedicine.drugMethadoneJournal of Palliative Medicine
researchProduct

Precision and Bias of Target-Controlled Prolonged Propofol Infusion for General Anesthesia and Sedation in Neurosurgical Patients

2018

The aim of this study was to determine the relationship, precision, and bias of a propofol target-controlled infusion (TCI) system during prolonged infusion in neurosurgical patients. We retrospectively included patients undergoing general anesthesia for elective neurosurgical removal of brain tumors and postoperative sedation in the intensive care unit over a period of 3 months. TCI of propofol (Diprifusor - Marsh model) and remifentanil were used for general anesthesia and sedation. We compared propofol blood concentration (Cmeas) measured by liquid chromatography-mass spectroscopy with predicted concentrations (Cpred) by the TCI system at 40 minutes (T0), 2 hours (T1), and 4 hours (T2) a…

AdultMaleTime FactorsSedationAnesthetic techniqueRemifentanilPharmacokineticAnesthesia GeneralMass SpectrometryNeurosurgical ProceduresTarget controlled infusionlaw.invention03 medical and health sciencesYoung Adult0302 clinical medicine030202 anesthesiologylawmedicineHumansPharmacology (medical)Computer-assisted continuous infusionPropofol TCILead (electronics)Infusions IntravenousPropofolAgedRetrospective StudiesPharmacologybusiness.industryBrain NeoplasmsPropofol infusionDrug administration030208 emergency & critical care medicineDrug infusionMiddle AgedIntensive care unitTolerabilityAnesthesiaLinear ModelsFemalemedicine.symptomPropofolbusinessAnesthetics Intravenousmedicine.drugChromatography LiquidTCI anesthesia
researchProduct